Table 2.

Immune checkpoint inhibitor–associated glomerular diseases

Glomerular disease	Drug	Reference
Minimal change disease	Ipilimumab Pembrolizumab	Kidd et al., 201626 Kitchlu et al., 201723 Kitchlu et al., 2017
Membranous nephropathy	Nivolumab	Mamlouk et al., 201924
Lupus nephritis	Ipilimumab Nivolumab	Fadel et al., 200922 Mamlouk et al., 201924
Pauci-immune glomerulonephritis	Nivolumab Tremelimumab Nivolumab and ipilimumab Ipilimumab + pembrolizumab Pembrolizumab	Mamlouk et al., 201924 Mamlouk et al., 201924 Mamlouk et al., 201924 Van den Brom et al., 201627 Gallan et al., 201925
IgA nephropathy	Pembrolizumab Nivolumab and ipilimumab Nivolumab	Mamlouk et al., 201924 Mamlouk et al., 201924 Jung et al., 201628 Kishi et al., 201829
C3 glomerulopathy	Pembrolizumab	Mamlouk et al., 201924
Focal segmental glomerulosclerosis	Nivolumab	Mamlouk et al., 201924 Daanen et al., 201730
Renal vasculitis	Nivolumab	Gallan et al., 201925